Demonstrated across multiple head-to-head trials.
Consider once-weekly Ozempic® for your adult patients with type 2 diabetes


CV safety as evaluated in a 2-year CVOT1,a,b
Ozempic® is not indicated for reduction in major adverse cardiovascular events (MACE).
CVOT=cardiovascular outcomes trial.
aThe primary composite endpoint was the time from randomization to first occurrence of a MACE: CV death, nonfatal myocardial infarction, or nonfatal stroke.
bResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial.
Ozempic® has been studied in a robust clinical trial program


Learn more about the clinical trials evaluating Ozempic®
What kind of trial are you looking for?